[ad_1]
CoronaVac, a vaccine developed in partnership by the Butantan Institute and the Chinese laboratory Sinovac, against COVID-19, proved to be effective in the phase 3 trial, carried out in Brazil, the American Wall Street Journal reported today.
However, Butantan does not confirm the information and says it will not report the results until December 23. The entity also points out that any news in this regard, before that date, is mere speculation.
“Butantan maintains its firm commitment to science, backed by 120 years of services in favor of life. We reiterate that all the press will be duly informed about the effectiveness of the vaccine, based on real data,” confirms the institute.
Brazil was the first country to complete the final phase of the clinical trial of the immunizer. After twice postponing the announcement of the result of the vaccine’s effectiveness, Butantan promised to show the degree of effectiveness on Wednesday (23). It will also file the CoronaVac registration application simultaneously in Brazil and China.
“The announcement will be made on the 23rd, at a time compatible with the two chronologies. In China, the regulatory body will receive data at the same time that our Anvisa (National Health Surveillance Agency) will also receive this data. And the Chinese regulatory body can quickly register this vaccine, ”explains Dimas Covas, president of the Butantan Institute.
The agency, linked to the São Paulo state government, will also request authorization from Anvisa for the emergency use of the vaccine. To be applied, the approval and registration of the agency is required. The state executive scheduled the start of vaccination for January 25, even without federal authorization.
Four immunizers are being tested in Brazil (CoronaVac, Pfizer / BioNtech, Janssen and Oxford / AstraZeneca), but none of them have yet been approved by Anvisa.
(With Reuters) *
